# Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

> **NCT00646529** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 175 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** budesonide/formoterol (Symbicort)
- **DRUG:** budesonide (Pulmicort)

## Key facts

- **NCT ID:** NCT00646529
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2003-10
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2009-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646529, "Long-Term Safety of Symbicort in Asthmatic Children - SAPLING". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00646529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*